Tamir Shragai

Tel Aviv, TA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 03, 2026

Can Belantamab mafodotin cause macro LDH?

Can Belantamab mafodotin cause macro LDH?

Journal: Leukemia & lymphoma
Published: April 16, 2026

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: April 04, 2026

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Histologic Transformation in Follicular Lymphoma: Real-World Outcomes with Rituximab vs. Obinutuzumab-Based Combinations.

Journal: Cancers
Published: March 30, 2026

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis.

Journal: Annals of hematology
Published: January 21, 2026

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Surveillance of Smoldering Myeloma Patients Who Progress to Active Disease Is Associated with Favorable Outcomes.

Journal: Cancers
Published: January 13, 2026

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Journal: Haematologica
Published: September 30, 2025

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica
Published: August 19, 2025

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.

The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non-Secretory Relapse-A Retrospective Cohort Study.

Journal: Hematological oncology
Published: May 22, 2025

Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples.

Deep-Learning-Based Prediction of t(11;14) in Multiple Myeloma H&E-Stained Samples.

Journal: Cancers
Published: April 17, 2025

Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience.

Clinical outcomes in older adults treated outside clinical studies: highlighting the octogenarian experience.

Journal: Blood advances
Published: January 21, 2025

The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment.

The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment.

Journal: Cancers
Published: August 20, 2024
Showing 1-12 of 25

Last Updated: 09/26/2026